1.  

Article types	Original article
Language	English
Refereed paper	Refereed
Title	Does first-line treatment have prognostic impact for unresectable HCC?-Atezolizumab plus bevacizumab versus lenvatinib
Journal	Formal name：Cancer Medicine
Domestic / Foregin	Foregin
Volume, Number, Page	12(1),pp.325-334
Papers・Author	Hiraoka Atsushi, Kumada Takashi, Tada Toshifumi, Hirooka Masashi, Kariyama Kazuya, Tani Joji, Atsukawa Masanori, Takaguchi Koichi, Itobayashi Ei, Fukunishi Shinya, Tsuji Kunihiro, Ishikawa Toru, Tajiri Kazuto, Ochi Hironori, Yasuda Satoshi, Toyoda Hidenori, Ogawa Chikara, Nishimura Takashi, Hatanaka Takashi, Kakizaki Satoru, Shimada Noritomo, Kawata Kazuhito, Naganuma Atsushi, Kosaka Hisashi, Shibata Hiroshi, Aoki Tomoko, Tanaka Takaaki, Ohama Hideko, Nouso Kazuhiro, Morishita Asahiro, Tsutsui Akemi, Nagano Takuya, Itokawa Norito, Okubo Tomomi, Arai Taeang, Imai Michitaka, Koizumi Yohei, Nakamura Shinichiro, Joko Kouji, Iijima Hiroko, Kaibori Masaki, Hiasa Yoichi, Kudo Masatoshi; Real-life Practice Experts for HCC (RELPEC) Study Group and HCC 48 Group (hepatocellular carcinoma experts from 48 clinics in Japan).
Publication date	2023